Help your Prostate Cancer Patients
Dive back into life
with confidence.
Proven suppression.1
Flexible dosing.1
Decades of experience.1
With over 4 million patient-years’ real-world experience
and proven efficacy and safety data from over 20 published clinical trials, you can be assured that ELIGARD™ will reliably suppress testosterone for as long as your patients need1-6
References
- ELIGARD SmPC. Latest version.
- Tolmar. PSUR. 2023. Data on File.
- Shore ND, et al. BJU Int. 2017;119:239–244.
- Perez-Marrero R, et al. Clin Ther. 2002;24:1902–1914.
- Chu FM, et al. J Urol. 2002;168:1199–1203.
- Crawford ED, et al. J Urol. 2006;175:533–536
This website is intended for healthcare professionals only.
ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent
advanced prostate cancer and for the treatment of high-risk localised and locally
advanced hormone dependent prostate cancer in combination with radiotherapy.1
GL-ELIGA-0020 | July 2025 © 2025 Recordati